Contact Congress about S. 113: Prescription Pricing for the People Act of 2023

The FTC would study drug supply chain middlemen, including PBMs. It would report to Congress on prices, competition, patient steering, and possible fixes. The bill does not directly lower drug prices or change PBM rules.

Modern Action explains what the legislation does, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Prescription Pricing for the People Act of 2023 is a Senate bill in Congress.

Who this affects: This bill mainly affects PBMs, other drug benefit middlemen, pharmacies, health plans, employers, drug makers, and patients. Patients would not see an immediate rule change. But the FTC report could shape future laws or enforcement that affect drug coverage, pharmacy choice, and prescription costs.

Why this matters: Drug prices can be shaped by companies most patients never deal with directly. This bill would make the FTC explain how those companies affect prices, pharmacy choice, and competition. The findings could help Congress decide whether new laws are needed. The bill’s direct effect is limited because it requires reports, not immediate price or rule changes.

Key provisions in S. 113

• The Federal Trade Commission must study drug supply chain middlemen. The study must include PBMs and pharmacy services administrative organizations, which help pharmacies deal with benefit plans.
• Congress must get two updates from the FTC. A progress report is due within 180 days, and the main report is due within one year after the bill becomes law.
• The FTC must look at major PBM practices. These include charging payers more than pharmacies receive, steering patients to PBM-owned pharmacies, using private pharmacy data, and shaping covered-drug lists in ways that affect high-cost and low-cost drugs.
• The FTC must study competition in the drug benefit market. It must also look at vertical integration, meaning companies owning or controlling several parts of the supply chain, such as middlemen, suppliers, and payers.
• The FTC must name any legal or rule barriers that make enforcement harder. This includes barriers to antitrust law, which protects competition, and consumer protection law, including barriers that may raise drug costs.

How Modern Action helps you take action on S. 113

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about S. 113

What is S. 113?

The FTC would study drug supply chain middlemen, including PBMs. It would report to Congress on prices, competition, patient steering, and possible fixes. The bill does not directly lower drug prices or change PBM rules.

How do I support or oppose S. 113?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about S. 113?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

How does Modern Action help me act on S. 113?

Modern Action gives you bill-specific context, lets you choose support, opposition, or changes, and drafts a message from your position and reasons.